Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...

MSD, known as Merck & Co Inc in the United States and Canada, has been in Singapore for 30 years, employs over 1,800 people, ...

In the trial, the combination of Padcev with Merck & Co.'s Keytruda showed a clinically meaningful and statistically significant improvement in event-free survival and overall survival when used ...

Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...

The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...